Developing radionuclide PARP inhibitors
Interviewee/Contributor
Greg Mullen
Organisation
Theragnostics Ltd
Drug discovery
The linker matters in antibody-drug conjugates
Interviewee/Contributor
Philipp Spycher
Organisation
Araris Biotech AG
The hunt for the perfect tumour-associated antigen
Interviewee/Contributor
Erik Manting
Organisation
DCPrime BV
Finding a link between the microbiome and disease
Interviewee/Contributor
Steff Taelman
Organisation
BioLizard NV
The role of oncolytic viruses in immuno-oncology
Interviewee/Contributor
Bernard Huber and Paul Higham
Organisation
Oryx GmbH & Co KG and Valo Therapeutics Ltd
Investors support new antifungal agent
Interviewee/Contributor
Ralf Schmid and Emma Harvey
Organisation
F2G Ltd
Evox developes exosomes as therapeutics
Interviewee/Contributor
Antonin de Fougerolles
Organisation
Evox Therapeutics Ltd
Unlocking the potential of PSMA as a cancer target
Interviewee/Contributor
Brian McGuinness and Theodora Harold
Organisation
Crescendo Biologics Ltd
Convalescent plasma hope in SARS-CoV-2 crisis
Interviewee/Contributor
Peter Charlish
Organisation
MedNous
What patients really want: involvement
Interviewee/Contributor
Pierre Meulien
Organisation
Innovative Medicines Initiative